Status: Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Apr 22, 2026Locations: 29
Eligibility criteria
Having histological confirmed diagnosis of malignancy [+5]
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or... [+12]